ASIT biotech: Publication Related to a Transparency Notification

BRUSSELS--(BUSINESS WIRE)--Regulatory News:

ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 24 September, 2018, the result of which is - following a capital increase completed on September 6^th – that SA S.R.I.B. and SA Brustart have now jointly 4,92% of the Company’s voting rights, and has thus decreased their stake below the 5% threshold.

The statement dated 24 September, 2018 notably includes the following information:

• Purpose of the notification

Passive crossing of a threshold

• Notification by

A parent undertaking or a controlling person

• Person subject to the notification requirement

S.R.I.B. SA – Rue Stassart 32, 1050 Bruxelles

Brustart SA – Rue Stassart 32, 1050 Bruxelles

• Date of the transaction

September 6^th, 2018

• Threshold crossed (%)

Downward crossing of the 5% threshold

• Denominator

A total of 17,506,777 voting rights

• This notification is available on ASIT biotech’s website, in the Documentation / Regulated information section:

  https://www.asitbiotech.com/investors/documentation

***

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at www.asitbiotech.com.